

238 structural equation modeling identifies differential links of pathologies and atrophy in dementia

Lena Haag^{1,2,†}, **Elisa Lancini**^{1,2,†}, **Renat Yakupov**^{1,2}, **Gabriel Ziegler**^{1,2}, **Yeo-Jin Yi**^{1,2}, **Wenzel Glanz**¹, **Falk Lüsenbrink**², **Oliver Peters**^{3,4}, **Eike Jakob Spruth**^{3,5}, **Slawek Altenstein**^{3,5}, **Josef Priller**^{3,5,6,7}, **Luisa-Sophie Schneiders**⁴, **Xiao Wang**⁴, **Lukas Preis**⁴, **Frederic Brosseron**⁸, **Nina Roy-Kluth**⁸, **Anja Schneider**^{8,9}, **Klaus Fliessbach**^{8,9}, **Michael Wagner**^{8,9}, **Steffen Wolfsgruber**^{8,9}, **Luca Kleineidam**^{8,9}, **Alfredo Ramirez**^{8,9,10,11,12}, **Annika Spottke**^{8,13}, **Frank Jessen**^{10,14,17}, **Jens Wiltfang**^{14,15,16}, **Niels Hansen**¹⁵, **Ayda Rostamzadeh**¹⁷, **Michael Ewers**¹⁸, **Katharina Buerger**^{18,19}, **Michael Ewers**^{18,19}, **Robert Perneczky**^{18,20,21,22}, **Daniel Janowitz**¹⁹, **Boris-Stephan Rauchmann**^{20,23,24}, **Stefan Teipel**^{25,26}, **Ingo Kilimann**^{25,26}, **Doreen Goerss**^{25,26}, **Christoph Laske**^{27,28}, **Matthias H. Munk**^{27,29}, **Michael T. Heneka**³⁰, **Peter Dechent**³¹, **Stefan Hetzer**³², **Klaus Scheffler**³³, **Emrah Dützel**^{1,2}, **Matthew J. Betts**^{1,2,34†}, **Dorothea Hämerer**^{1,2,35,36†}

1 Institute of Cognitive Neurology and Dementia Research (IKND), 39120 Magdeburg, Germany / 2 German Center for Neurodegenerative Diseases (DZNE), 39120 Magdeburg, Germany / 3 German Center for Neurodegenerative Diseases (DZNE), 10117 Berlin, Germany / 4 Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Psychiatry and Psychotherapy / 5 Department of Psychiatry and Psychotherapy, Charité, Charitéplatz 1, 10117 Berlin, Germany / 6 School of Medicine, Technical University of Munich; Department of Psychiatry and Psychotherapy, 81675 Munich, Germany / 7 University of Edinburgh and UK DRI, Edinburgh, UK
8 German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127 Bonn, Germany / 9 University of Bonn Medical Center, Dept. of Neurodegenerative Disease and Geriatric Psychiatry/Psychiatry, Venusberg-Campus 1, 53127 Bonn, Germany / 14 German Center for Neurodegenerative Diseases (DZNE), 37075 Goettingen, Germany / 15 Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, University of Goettingen, Von-Siebold-Str. 5, 37075 Goettingen / 16 Neurosciences and Signaling Group, Institute of Biomedicine (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal / 17 Department of Psychiatry, University of Cologne, Medical Faculty, Kerpener Strasse 62, 50924 Cologne, Germany / 10 Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Strasse 26, 50931 Köln, Germany / 11 Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50931 Cologne, Germany / 12 Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA / 13 Department of Neurology, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany / 18 German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Strasse 17, 81377 Munich, Germany / 19 Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Feodor-Lynen-Strasse 17, 81377 Munich, Germany / 20 Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany / 21 Munich Cluster for Systems Neurology (SyNergy) Munich, Munich, Germany / 22 Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, UK / 23 Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK / 24 Department of Neuroradiology, University Hospital LMU, Munich, Germany / 25 German Center for Neurodegenerative Diseases (DZNE), 18147 Rostock, Germany
26 Department of Psychosomatic Medicine, Rostock University Medical Center, Gehlsheimer Str. 20, 18147 Rostock / 27 German Center for Neurodegenerative Diseases (DZNE), 72076 Tübingen, Germany / 28 Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany / 29 Department of Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany
30 Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4367 Belvaux / 31 MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University Goettingen, Germany / 32 Berlin Center for Advanced Neuroimaging, Charité – Universitätsmedizin Berlin, Berlin, Germany / 33 Department for Biomedical Magnetic Resonance, University of Tübingen, 72076 Tübingen, Germany / 34 Center for Behavioral Brain Sciences, University of Magdeburg, 39120 Magdeburg, Germany / 35 Department of Psychology, University of Innsbruck, 6020 Innsbruck, Austria / 36 Institute of Cognitive Neuroscience, University College London, London WC1N 3AZ, UK

Question

Neuromodulatory systems exhibit particular vulnerability to protein pathologies in dementia¹

Do brain areas more reliant on neuromodulation (higher receptor densities) show more atrophy linked to protein pathologies?

Method


- Data from the DZNE DELCODE sample²
 - N = 400 older adults split in 3 groups:
 - 122 Healthy controls (HC, 67.75 years (SD 4.97)
 - 152 subjective cognitive decline (SCD, 70.35 years (SD 5.77)
 - 126 MCI/AD, 72.88 years (SD 5.67)
 - Volumes of brain areas split according to receptor densities high and low, based on: <https://www.proteinatlas.org>
 - Structural equation modeling using lavaan³ in R

Conclusions


- Protein pathologies are in particular linked to decline in areas high in NA receptors
 - Distinct links of cognitive function and atrophy across areas more dependent on NA, DA, SE or ACh
 - Levels of tau & amyloid pathologies are correlated in SCD (and MCI/AD), but not in HC

Results


Noradrenaline (NA)




Dopamine (DA)



Serotonin (SE)



Acetylcholin (Ach)



Subgroups: Healthy controls (HC) & Subjective cognitive decline (SCD) / Mild Cognitive Impairment (MCI) / Alzheimer's Disease (AD)

| | Noradrenaline | | | | Dopamine | | | | Serotonin | | | | Acetylcholin |
|---------------------------------|------------------------|--------------------------|------------------------|------------------------|------------------------|--------------------------|------------------------|------------------------|------------------------|--------------------------|------------------------|------------------------|------------------------|
| | Whole sample (n = 400) | HC + relatives (n = 122) | SCD (n = 152) | MCI/AD (n = 126) | Whole sample (n = 400) | HC + relatives (n = 122) | SCD (n = 152) | MCI/AD (n = 126) | Whole sample (n = 400) | HC + relatives (n = 122) | SCD (n = 152) | MCI/AD (n = 126) | Whole sample (n = 400) |
| CFI | 0.918 | | 0.904 | | 0.922 | | 0.892 | | 0.940 | | 0.916 | | 0.921 |
| TLI | 0.857 | | 0.858 | | 0.864 | | 0.840 | | 0.896 | | 0.875 | | 0.863 |
| RMSEA | 0.095 | | 0.080 | | 0.087 | | 0.080 | | 0.079 | | 0.073 | | 0.094 |
| SRMR | 0.081 | | 0.086 | | 0.072 | | 0.088 | | 0.057 | | 0.077 | | 0.068 |
| p-tau ↔ Aβ42/40 | -0.405*** | -0.119 ^a | -0.366*** ^a | -0.424*** ^a | -0.405*** | -0.119 ^a | -0.366*** ^a | -0.424*** ^a | -0.405*** | -0.119 ^a | -0.366*** ^a | -0.424*** ^a | -0.405*** |
| high areas ↔ low areas | 0.702*** | 0.713*** | 0.594*** | 0.613*** | 0.578*** | 0.607*** | 0.504*** | 0.471*** | 0.784*** | 0.406** ^a | 0.687*** ^a | 0.860*** ^a | 0.947*** |
| p-tau → high areas | -0.066 | 0.004 | 0.006 | 0.010 | -0.059 | -0.027 | -0.034 | -0.056 | -0.052 | 0.035 | 0.053 | 0.082 | -0.082 |
| p-tau → low areas | -0.050 | -0.010 | -0.011 | -0.018 | 0.073 | 0.073* | 0.110* | 0.175* | -0.062 | 0.006 | 0.007 | 0.010 | -0.108 |
| Aβ42/40 → high areas | 0.237*** | 0.113* | 0.127* | 0.142* | 0.213** | 0.117 | 0.115 | 0.127 | 0.164** | 0.037 | 0.044 | 0.046 | 0.245*** |
| Aβ42/40 → low areas | 0.141* | 0.071 | 0.066 | 0.069 | 0.103 | 0.015 | 0.018 | 0.019 | 0.219** | 0.114 | 0.119 | 0.108 | 0.228** |
| high areas → memory | 0.489*** | 0.156 | 0.147 | 0.092 | 0.201* | 0.171 | 0.185 | 0.118 | 0.314** | -0.010 | -0.009 | -0.006 | -0.691 |
| high areas → language | 0.272* | -0.004 | -0.004 | -0.003 | 0.233** | 0.200* | 0.223* | 0.141* | 0.285* | -0.066 | -0.062 | -0.042 | -1.730 |
| high areas → executive function | 0.150 | -0.065 | -0.057 | -0.040 | 0.180* | 0.160 | 0.161 | 0.114 | 0.280* | -0.050 | -0.042 | -0.031 | -1.726 |
| high areas → working memory | 0.086 | -0.127 | -0.114 | -0.083 | 0.101 | 0.024 | 0.024 | 0.018 | 0.358** | 0.096 | 0.081 | 0.064 | -2.127 |
| high areas → visual memory | 0.229* | -0.044 | -0.041 | -0.030 | 0.079 | -0.020 | -0.022 | -0.016 | 0.389** | 0.072 | 0.064 | 0.049 | -1.211 |
| low areas → memory | -0.081 | 0.017 | 0.020 | 0.013 | 0.148 | -0.074 | -0.066 | -0.043 | 0.110 | 0.161 | 0.165 | 0.128 | 1.198 |
| low areas → language | 0.078 | 0.143 | 0.169 | 0.113 | 0.146 | -0.060 | -0.055 | -0.036 | 0.164 | 0.249* | 0.266* | 0.204* | 2.185 |
| low areas → executive function | 0.122 | 0.159 | 0.169 | 0.126 | 0.159 | -0.033 | -0.027 | -0.020 | 0.105 | 0.192 | 0.183 | 0.157 | 2.089 |
| low areas → working memory | 0.110 | 0.114 | 0.124 | 0.097 | 0.223* | 0.087 | 0.073 | 0.056 | -0.002 | 0.022 | 0.021 | 0.019 | 2.446 |
| low areas → visual memory | -0.034 | 0.020 | 0.023 | 0.017 | 0.147 | -0.011 | -0.010 | -0.008 | -0.114 | -0.039 | -0.039 | -0.035 | 1.509 |
| p-tau → memory | -0.183*** | -0.116** | -0.155** | -0.163** | -0.210*** | -0.106** | -0.143** | -0.149** | -0.188*** | -0.117** | -0.158** | -0.167** | -0.138 |
| p-tau → language | -0.154*** | -0.070 | -0.097 | -0.102 | -0.173*** | -0.061 | -0.085 | -0.089 | -0.151*** | -0.070 | -0.099 | -0.104 | -0.081 |
| p-tau → executive function | -0.140** | -0.062 | -0.077 | -0.090 | -0.157*** | -0.056 | -0.070 | -0.082 | -0.135** | -0.062 | -0.078 | -0.092 | -0.072 |
| p-tau → working memory | -0.152** | -0.061 | -0.077 | -0.095 | -0.174*** | -0.068 | -0.086 | -0.106 | -0.145** | -0.066 | -0.084 | -0.103 | -0.073 |
| p-tau → visual memory | -0.134** | -0.058 | -0.077 | -0.092 | -0.153*** | -0.057 | -0.077 | -0.091 | -0.134** | -0.061 | -0.081 | -0.098 | -0.083 |
| Aβ42/40 → memory | 0.185*** | 0.110* | 0.116* | 0.082* | 0.231*** | 0.111* | 0.118* | 0.082* | 0.214*** | 0.107* | 0.115* | 0.081* | 0.185* |
| Aβ42/40 → language | 0.221*** | 0.120* | 0.132* | 0.092* | 0.232*** | 0.108* | 0.119* | 0.083* | 0.214*** | 0.099 | 0.110 | 0.077 | 0.223 |
| Aβ42/40 → executive function | 0.251*** | 0.157** | 0.155** | 0.121** | 0.248*** | 0.143* | 0.141* | 0.110* | 0.234*** | 0.136* | 0.136* | 0.106* | 0.250* |
| Aβ42/40 → working memory | 0.217*** | 0.094 | 0.095 | 0.078 | 0.209*** | 0.084 | 0.085 | 0.070 | 0.195*** | 0.081 | 0.082 | 0.067 | 0.217 |

Figures above: Relationships between protein pathologies, brain volumes and cognitive functions are assessed while controlling for influences of interindividual differences in: ApoE4 Status, age, education level, white matter hyperintensities and gender (not shown here). Numbers in brackets indicate explained variance of respective variable /factor

Table left: Multigroup analyses examine links from Figures above within HC, SCD, MCI/AD subgroups. Links between protein pathologies and areas high in NA and low in DA receptors prevailed also within subgroups. Higher levels in protein pathologies were generally linked to worse cognitive performance, also within subgroups (not shown in Figures above for the sake of clarity). Assessing subgroups in Ach was not possible as models did not converge, likely due to subgroups not being sufficiently different in variance patterns.

References

- 1** Betts, M. J., Kirilina, E., Otaduy, M. C. G., Ivanov, D., Acosta-Cabronero, J., Callaghan, M. F., Lambert, C., Cardenas-Blanco, A., Pine, K., Passamonti, L., Loane, C., Keuken, M. C., Trujillo, P., Lüsebrink, F., Mattern, H., Liu, K. Y., Priovoulos, N., Fliessbach, K., Dahl, M. J., ... Hä默er, D. (2019). Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. *Brain*, 142(9), 2558–2571.
<https://doi.org/10.1093/brain/awz193>

2 Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*. 2018;10(1):15. doi:10.1186/s13195-

- 2** Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther.* 2018;10(1):15. doi:10.1186/s13195-017-0214-6

- 3** Rosseel Y (2012). “lavaan: An R Package for Structural Equation Modeling.” *Journal of Statistical Software*, **48**(2), 1–36.